search
Back to results

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Primary Purpose

Mantle Cell Lymphoma

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
R-CHOP/R-DHAP
Ibrutinib (Induction)
ASCT conditioning
Ibrutinib (Maintenance)
Sponsored by
Prof. Dr. M. Dreyling (co-chairman)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mantle Cell Lymphoma focused on measuring MCL

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All patients must meet the following criteria:

  • Histologically confirmed diagnosis of MCL according to WHO classification
  • suitable for high-dose treatment including high-dose Ara-C
  • Stage II-IV (Ann Arbor)
  • Age ≥ 18 years and ≤ 65 years
  • Previously untreated MCL
  • At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations.
  • ECOG/WHO performance status ≤ 2

  • The following laboratory values at screening (unless related to MCL):

    • Absolute neutrophil count (ANC) ≥1000 cells/µL
    • Platelets ≥100,000 cells/µL
    • Transaminases (AST and ALT) ≤3 x upper limit of normal (ULN)
    • Total bilirubin ≤2 x ULN unless due to known Morbus Meulengracht [Gilbert-Meulengracht-Syndrome])
    • Creatinine ≤2 mg/dL or calculated creatinine clearance ≥ 50 mL/min
  • Written informed consent form according to ICH/EU GCP and national regulations
  • Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug.

Exclusion Criteria:

Any potential subject who meets any of the following criteria will be excluded from participating in the study.

  • Major surgery within 4 weeks prior to randomization.
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg phenprocoumon).
  • History of stroke or intracranial hemorrhage within 6 months prior to randomization.
  • Requires treatment with strong CYP3A4/5 inhibitors.
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
  • Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.
  • Known CNS involvement of MCL
  • Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of ibrutinib itself or to the excipients in its formulation)
  • Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies
  • Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy according to trial protocol

  • Serious concomitant disease interfering with a regular therapy according to the study protocol:

    • Cardiac (Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below LLN )
    • Pulmonary (e.g. chronic lung disease with hypoxemia)
    • Endocrinological (e.g. severe, not sufficiently controlled diabetes mellitus)
    • Renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinin clearance < 50 ml/min)
    • Impairment of liver function (unless caused by the lymphoma): transaminases > 3x normal or bilirubin > 2,0 mg/dl unless due to morbus Meulengracht (Gilbert-Meulengracht-Syndrome)
  • Patients with unresolved hepatitis B or C infection or known HIV positive infection (mandatory test)
  • Prior organ, bone marrow or peripheral blood stem cell transplantation
  • Concomitant or previous malignancies within the last 3 years other than basal cell skin cancer or in situ uterine cervix cancer
  • Pregnancy or lactation
  • Any psychological, familiar, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule
  • Subjects not able to give consent
  • Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial
  • Participation in another clinical trial within 30 days before randomization in this study.

Sites / Locations

  • Aalborg University Hospital, Dept of Hematology
  • Aarhus University Hospital, Dept of Hematology
  • Rigshospitalet, Clinic of Hematology
  • Herlev Hospital, Department of Hematology L121
  • Odense University Hospital, Dept of Hematology X
  • Sjaelland University Hospital, Dept of Hematology
  • Zentralklinik Augsburg, II. Med. Klinik, Hämatologie int. OnkologieRecruiting
  • Onkologische Gemeinschaftspraxis Dr. Janssen/Dr. Reichert in der Ubbo-Emmius-KlinikRecruiting
  • Klinikum Bayreuth, Klinik f. Onkologie und HämatologieRecruiting
  • Vivantes Klinikum Am Urban, Klinik f. Innere Medizin, Hämatologie und OnkologieRecruiting
  • Charité Univ.-Medizin Berlin, Med. Klinik - Hämatologie, Onkologie und Tumorimmunologie
  • Helios Klinikum Berlin-Buch, Hämatologie, Onkologie und TumorimmunologieRecruiting
  • Knappschaftskrankenhaus Bochum-LangendreerRecruiting
  • Universitätsklinikum BonnRecruiting
  • Diako ev. Diakonie-KH gGmbH, Med. Klinik II, Hämatologie und OnkologieRecruiting
  • Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin IIRecruiting
  • DONAUISAR Klinikum Deggendorf, Innere Medizin IIRecruiting
  • St.-Johannes-HospitalRecruiting
  • Gemeinschaftspraxis Dr. Mohm und Prange-Krex - Fachärzte für Innere Medizin und Hämatologie und OnkologieRecruiting
  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität DresdenRecruiting
  • Universitätsklinikum Düsseldorf, Klinik f. Hämatologie, Onkologie und klinische ImmunologieRecruiting
  • Marien Hospital DüsseldorfRecruiting
  • Helios Klinikum Erfurt GmbH, Zentrum f. Innere Medizin u. internistische Onkologie, HämostaseologieRecruiting
  • Universitätsklinikum Erlangen, Med. Klinik 5, Hämatologie und internistische OnkologieRecruiting
  • St.-Antonius-Hospital Eschweiler, Klinik für Hämatologie und OnkologieRecruiting
  • Universitätsklinikum Essen, Klinik f. HämatologieRecruiting
  • Universitätsklinikum Freiburg, Klinik f. Innere Medizin, Hämatologie, Onkologie u. StammzelltransplantationRecruiting
  • Universitätsmedizin Greifswald, Klinik u. Poliklinik f. Innere Medizin C, Hämatologie u. Onkologie-, TransplantationszentrumRecruiting
  • Universitätsmedizin Göttingen, Zentrum f. Innere Medizin, Klinik f. Hämatologie und Medizinische OnkologieRecruiting
  • Katholisches Krankenhaus Hagen gGmbH, St.-Marien-Hospital, Klinik f. Hämatologie und OnkologieRecruiting
  • Universitätsklinikum Hamburg-Eppendorf (UKE), II. Med. Klinik u. Poliklinik, Onkologie, Hämatologie, KMTRecruiting
  • Asklepios Klinik Altona, II. Med.Abt. f. Hämatologie und internistische Onkologie, StammzelltransplantationRecruiting
  • Universitätsklinikum Heidelberg, Med. Klinik - Innere Medizin V - Hämatologie, Onkologie und RheumatologieRecruiting
  • Universitätsklinikum des Saarlandes, Klinik f. Innere Medizin I Hämatologie & OnkologieRecruiting
  • Klinikum Idar-Oberstein GmbH, Medizinische Klinik IRecruiting
  • Universitätsmedizin Jena, Klinik f. Innere Medizin II, Abteilung Hämatologie u. Internistische OnkologieRecruiting
  • Städtisches Klinikum Karlsruhe, Med. Klinik III, Hämatologie und OnkologieRecruiting
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik f. Innere Medizin II - Hämatologie und OnkologieRecruiting
  • Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin, Klinik f. Innere MedizinRecruiting
  • Praxisklinik f. Hämatologie und Onkologie KoblenzRecruiting
  • Uniklinik Köln, Klinik I für Innere MedizinRecruiting
  • Onkologisch-Hämatologische Praxis Dr. Vehling-KaiserRecruiting
  • Klinikum Landshut gGmbH, Med. Klinik III, Hämatologie/Internistische OnkologieRecruiting
  • Caritas-KHLebach, Gemeinschaftspraxis f. Hämatologie und Onkologie, Onkologisches Zentrum LebachRecruiting
  • Universitätsklinikum Leipzig AöR, selbständige Abteilung f. Hämatologie und Internistische Onkologie, Hämostaseologische AmbulanzRecruiting
  • Klinikum Lippe GmbH, Onkologie und HämatologieRecruiting
  • Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Med. Klinik ARecruiting
  • Universitätsklinikum Magdeburg AöR, Klinik f. Hämatologie und OnkologieRecruiting
  • Universitätsmedizin der Univ. Mainz, III. Med. Klinik u. PoliklinikRecruiting
  • Johannes Wiesling Klinikum Minden, Klinik f. Hämatologie/Onkologie, Hämostaseologie und PalliativmedizinRecruiting
  • Klinikum der Universität München, Med. Klinik und Poliklinik IIIRecruiting
  • Klinikum Rechts der Isar, III. Med. Klinik - Hämatologie und OnkologieRecruiting
  • Universitätsklinikum Münster, Med. Klinik A, Translationale Onkologie / LymphomeRecruiting
  • Klinikum Nürnberg,5. Medizinische Klinik, Onkologie / HämatologieRecruiting
  • Klinikum Oldenburg gGmbH, Med. Klinik IIRecruiting
  • Klinikum Ernst von Bergmann Potsdam gGmbH, Zentrum f. Innere Medizin, Klinik f. Hämatologie und OnkologieRecruiting
  • KH Barmherzige Brüder, Klinik f. Onkologie und HämatologieRecruiting
  • Universitätsmedizin Rostock, Abt. f. Hämatologie und Onkologie, Klinik und Poliklinik für Innere MedizinRecruiting
  • Klinikum Stuttgart - Katharinenhospital, Klinik f. Hämatologie und OnkologieRecruiting
  • Robert-Bosch-Krankenhaus, Abt.f. Hämatologie und OnkologieRecruiting
  • Klinikum Traunstein, Hämatologie - Onkologie- PalliativmedizinRecruiting
  • Klinikum Mutterhaus der Borromäerinnen gGmbH, Okologisches ZentrumRecruiting
  • Universitätsklinikum Tübingen, Med Klinik I, Innere Medizin IIRecruiting
  • Universitätsklinikum Ulm, Klinik für Innere Medizin IIIRecruiting
  • Klinikum Wolfsburg, Med. Klinik IIRecruiting
  • Universitätsklinikum Würzburg, Med. Klinik u. Poliklinik II /ZIM
  • Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, SC EmatologiaRecruiting
  • Policlinico S. Orsola Malpighi, Istituto di Ematologia e Oncologia Medica Seragnoli
  • Comprensorio Sanitario di Bolzano, Ematologia e trapianto di midollo osseo
  • Spedali Civili, Struttura Complessa di Ematologia
  • Ospedale Businco, UO Ematologia - CTMO
  • ASO S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
  • AOU Policlinico Careggi, Unità Funzionale di Ematologia
  • IRCCS AOU S. Martino - IST, Clinica Ematologia
  • IRCCS AOU S. Martino - IST, Ematologia
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Ematologia
  • Istituto Scientifico San Raffaele, Unità Ricerca Clinica Linfomi
  • Ospedale Niguarda, Struttura Complessa di Ematologia
  • Università di Modena e Reggio Emilia Policlinico - COM Centro Oncologico Modenese, Dipartimento di Oncologia ed Ematologia
  • Ospedale S. Gerardo, Divisione di Ematologia
  • "IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale", Ematologia OncologicaRecruiting
  • AOU Maggiore della Carità - Università del Piemonte Orientale, S.C.D.U Ematologia
  • AO Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia
  • IRCCS Fondazione Policlinico San Matteo, Clinica Ematologia
  • Azienda Ospedaliera Pisana Ospedale "S.Chiara", Dipartimento di Oncologia Divisione di Ematologia
  • Ospedale S. Maria delle Croci, U.O di Ematologia
  • Azienda Ospedaliera Bianchi, Melacrino, Morelli, Divisione di Ematologia
  • Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Ematologia
  • Ospedale degli Infermi, U.O. Ematologia
  • Policlinico Tor Vergata, UOC Oncoematologia
  • Università La Sapienza, Ematologia
  • Casa Sollievo della Sofferenza, U.O. Ematologia
  • A.O. Città della Salute e della Scienza, SC Ematologia
  • A.O. U. Città della Salute e della Scienza, S C Ematologia U
  • Ospedale Cà Foncello, U.O.C. Ematologia
  • Ospedale Cardinale Panico, Divisione di Ematologia
  • ASUI Integrata di Udine, Clinica Ematologia
  • Ospedale Policlinico G.B. Rossi, "Centro trapianto midollo osseo Ematologia"Recruiting
  • Ospedale S. Bortolo, EmatologiaRecruiting
  • Haukeland University Hospital , Dept. of Oncology and Medical Physics
  • Oslo University Hospital, Dept of Oncology
  • Stavanger University Hospital, Division for Hematology&Oncology
  • UNN Tromsø, Oncology Dep
  • St. Olavs Hospital, Department of Oncology
  • Sahlgrenska University Hospital, Section of Hematology and Coagulation, Dept of internal medicine
  • University Hospital, Dept of HematolgyRecruiting
  • Sunderbyn Hospital, Dept of Medicine
  • Skane University HospitalRecruiting
  • Karolinska University Hospital, Center of HematologyRecruiting
  • Norrland University Hospital, Dept of Oncology
  • Academic Hospital, Dept of OncologyRecruiting
  • Örebro University Hospital, Dept of OncologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Standard Arm A

Experimental Arm A+I

Experimental Arm I

Arm Description

R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM

R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction) ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM 2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)

R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction) 2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)

Outcomes

Primary Outcome Measures

Failure Free Survival

Secondary Outcome Measures

Overall Survival
Number of participants with treatment-related adverse events as assessed by CTC Version 4.03
Safety and tolerability
Progression-free survival (PFS)
Number of Secondary Primary Malignancies
Toxicity Endpoints
Number of Adverse Events by CTC grade (Version 4.03)
Toxicity Endpoints

Full Information

First Posted
July 14, 2016
Last Updated
December 17, 2017
Sponsor
Prof. Dr. M. Dreyling (co-chairman)
Collaborators
LMU Klinikum
search

1. Study Identification

Unique Protocol Identification Number
NCT02858258
Brief Title
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Official Title
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Recruiting
Study Start Date
July 2016 (undefined)
Primary Completion Date
May 2021 (Anticipated)
Study Completion Date
May 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Dr. M. Dreyling (co-chairman)
Collaborators
LMU Klinikum

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.
Detailed Description
Objectives and Endpoints Primary Objective: To establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A), R-CHOP+ibrutinib /R-DHAP followed by ASCT and ibrutinib maintenance experimental arm A+I), and R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance experimental arm I) as future standard based on the comparison of the investigator-assessed failure-free survival (FFS). Secondary Objectives: To compare the efficacy of the three treatment arms in terms of secondary efficacy endpoints To determine the safety and tolerability of ibrutinib during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints Primary Endpoint: FFS defined as time from start of treatment to stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause. Secondary Efficacy Endpoints: Overall survival (OS) Progression-free survival (PFS) from randomization, from end of induction immuno-chemotherapy in patients with CR or PR at end of induction immuno-chemotherapy, and from the staging 6 weeks after end of induction assessment (at month 6) Overall response and complete remission rates at midterm, at end of induction, 3 months after end of induction immunochemotherapy (at month 6) PR to CR conversion rate during follow-up after end of induction immuno-chemotherapy Secondary Toxicity Endpoints: Rates of AEs, SAEs, and SUSARs by CTC grade (Version 4.03) during induction immuno-chemotherapy and during periods of follow-up after response to immune-chemotherapy Cumulative incidence rates of SPMs Exploratory Objectives: To compare feasibility of ASCT in arm A+I vs. arm A To compare minimal residual disease status between the three treatment groups To determine the impact of ibrutinib during induction immuno-chemotherapy and during maintenance therapy on the minimal residual disease status To determine the prognostic value of minimal residual disease status To determine the prognostic value of positron emission tomography with fluorine 18-fluorodeoxyglucose To determine clinical and biological prognostic and predictive factors To determine the role of total body irradiation (TBI) in ASCT conditioning Exploratory Endpoints: Rate of successful stem cell mobilisations (success: separation of at least 2x2x10(6) CD34-positive cells, including a back-up) Rate of molecular remissions (MRD-negative patients) at midterm, at end of induction immuno-chemotherapy, and at staging time-points during follow-up in patients with remission after end of induction immuno-chemotherapy Time to molecular remission from start of therapy Time to molecular relapse for patients in clinical and molecular remission after end of induction immunochemotherapy RD in FDG-PET negative or positive patients after induction and ASCT Exploratory objectives may be evaluated only in a subset of patients according to local standards and resources.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mantle Cell Lymphoma
Keywords
MCL

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
870 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard Arm A
Arm Type
Active Comparator
Arm Description
R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM
Arm Title
Experimental Arm A+I
Arm Type
Experimental
Arm Description
R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction) ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM 2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)
Arm Title
Experimental Arm I
Arm Type
Experimental
Arm Description
R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction) 2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)
Intervention Type
Drug
Intervention Name(s)
R-CHOP/R-DHAP
Other Intervention Name(s)
rituximab, CHOP, DHAP
Intervention Description
Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
Intervention Type
Drug
Intervention Name(s)
Ibrutinib (Induction)
Other Intervention Name(s)
Imbruvica
Intervention Description
Ibrutinib: only in cycle 1,3,5 on Day 1-19
Intervention Type
Drug
Intervention Name(s)
ASCT conditioning
Other Intervention Name(s)
THAM or BEAM
Intervention Description
ASCT conditioning THAM or BEAM, stratified per site before trial activation at site THAM (TBI (total body irradiation), Ara-C, Melphalan) or BEAM (BCNU, Etoposide, Cytarabine, Melphalan)
Intervention Type
Drug
Intervention Name(s)
Ibrutinib (Maintenance)
Other Intervention Name(s)
Imbruvica
Intervention Description
Ibrutinib (Maintenance), daily 560 mg for 2 years;
Primary Outcome Measure Information:
Title
Failure Free Survival
Time Frame
From start of treatment until stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause, whichever comes first, assessed up to 120 months.
Secondary Outcome Measure Information:
Title
Overall Survival
Time Frame
From start of treatment until the date of first documented progression, assessed up to 120 months.
Title
Number of participants with treatment-related adverse events as assessed by CTC Version 4.03
Description
Safety and tolerability
Time Frame
From start of Ibrutinib treatment during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints. Through study conduction, an average of up to 30 months.
Title
Progression-free survival (PFS)
Time Frame
PFS is the time to progression or death from any cause. Assed up to 120 months.
Title
Number of Secondary Primary Malignancies
Description
Toxicity Endpoints
Time Frame
From start of treatment through the study conduction, up to 120 months.
Title
Number of Adverse Events by CTC grade (Version 4.03)
Description
Toxicity Endpoints
Time Frame
From start of treatment through the study conduction, up to 120 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients must meet the following criteria: Histologically confirmed diagnosis of MCL according to WHO classification suitable for high-dose treatment including high-dose Ara-C Stage II-IV (Ann Arbor) Age ≥ 18 years and ≤ 65 years Previously untreated MCL At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations. ECOG/WHO performance status ≤ 2 The following laboratory values at screening (unless related to MCL): Absolute neutrophil count (ANC) ≥1000 cells/µL Platelets ≥100,000 cells/µL Transaminases (AST and ALT) ≤3 x upper limit of normal (ULN) Total bilirubin ≤2 x ULN unless due to known Morbus Meulengracht [Gilbert-Meulengracht-Syndrome]) Creatinine ≤2 mg/dL or calculated creatinine clearance ≥ 50 mL/min Written informed consent form according to ICH/EU GCP and national regulations Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug. Exclusion Criteria: Any potential subject who meets any of the following criteria will be excluded from participating in the study. Major surgery within 4 weeks prior to randomization. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg phenprocoumon). History of stroke or intracranial hemorrhage within 6 months prior to randomization. Requires treatment with strong CYP3A4/5 inhibitors. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization. Known CNS involvement of MCL Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of ibrutinib itself or to the excipients in its formulation) Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy according to trial protocol Serious concomitant disease interfering with a regular therapy according to the study protocol: Cardiac (Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below LLN ) Pulmonary (e.g. chronic lung disease with hypoxemia) Endocrinological (e.g. severe, not sufficiently controlled diabetes mellitus) Renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinin clearance < 50 ml/min) Impairment of liver function (unless caused by the lymphoma): transaminases > 3x normal or bilirubin > 2,0 mg/dl unless due to morbus Meulengracht (Gilbert-Meulengracht-Syndrome) Patients with unresolved hepatitis B or C infection or known HIV positive infection (mandatory test) Prior organ, bone marrow or peripheral blood stem cell transplantation Concomitant or previous malignancies within the last 3 years other than basal cell skin cancer or in situ uterine cervix cancer Pregnancy or lactation Any psychological, familiar, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule Subjects not able to give consent Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial Participation in another clinical trial within 30 days before randomization in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Döndü Gözel
Phone
+49 89 4400
Ext
77906
Email
Doendue.Goezel@med.uni-muenchen.de
First Name & Middle Initial & Last Name or Official Title & Degree
Christian Schmidt, Dr.
Phone
+49 89 4400
Ext
74900
Email
Christian_Schmidt@med.uni-muenchen.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Dreyling, Prof.
Organizational Affiliation
Klinikum der Universität München
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aalborg University Hospital, Dept of Hematology
City
Aalborg
ZIP/Postal Code
9000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Herdis Larsen, Dr.
Facility Name
Aarhus University Hospital, Dept of Hematology
City
Aarhus C
ZIP/Postal Code
8000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans Bentzen, Dr.
Facility Name
Rigshospitalet, Clinic of Hematology
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Hutchings, Dr.
Facility Name
Herlev Hospital, Department of Hematology L121
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pär Lars Josefsson
First Name & Middle Initial & Last Name & Degree
Danny Stoltenberg
Facility Name
Odense University Hospital, Dept of Hematology X
City
Odense C
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacob Haaber Christensen, Dr.
Facility Name
Sjaelland University Hospital, Dept of Hematology
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Bjorn Poulsen, Dr.
Facility Name
Zentralklinik Augsburg, II. Med. Klinik, Hämatologie int. Onkologie
City
Augsburg
ZIP/Postal Code
86156
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Schmid, PD Dr.
First Name & Middle Initial & Last Name & Degree
Andreas Rank, PD Dr.
Facility Name
Onkologische Gemeinschaftspraxis Dr. Janssen/Dr. Reichert in der Ubbo-Emmius-Klinik
City
Aurich
ZIP/Postal Code
26603
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Janssen, Dr.
First Name & Middle Initial & Last Name & Degree
Dietmar Reichert, Dr.
Facility Name
Klinikum Bayreuth, Klinik f. Onkologie und Hämatologie
City
Bayreuth
ZIP/Postal Code
95445
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Kiani, Prof.
First Name & Middle Initial & Last Name & Degree
Armin Leitner, Dr.
Facility Name
Vivantes Klinikum Am Urban, Klinik f. Innere Medizin, Hämatologie und Onkologie
City
Berlin
ZIP/Postal Code
10967
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Scholz, PD Dr.
First Name & Middle Initial & Last Name & Degree
Annette Dierig, Dr.
Facility Name
Charité Univ.-Medizin Berlin, Med. Klinik - Hämatologie, Onkologie und Tumorimmunologie
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio Pezzutto, Prof.
First Name & Middle Initial & Last Name & Degree
Corinna Leng, Dr.
Facility Name
Helios Klinikum Berlin-Buch, Hämatologie, Onkologie und Tumorimmunologie
City
Berlin
ZIP/Postal Code
13125
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephan Fuhrmann, Dr.
Facility Name
Knappschaftskrankenhaus Bochum-Langendreer
City
Bochum
ZIP/Postal Code
44892
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wolff Schmiegel, Prof. Dr.
Facility Name
Universitätsklinikum Bonn
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Zipfel, Dr.
First Name & Middle Initial & Last Name & Degree
Johannes Heiders, Dr.
First Name & Middle Initial & Last Name & Degree
Karin Mayer, Dr.
First Name & Middle Initial & Last Name & Degree
Roland Kronenberger, Dr.
Facility Name
Diako ev. Diakonie-KH gGmbH, Med. Klinik II, Hämatologie und Onkologie
City
Bremen
ZIP/Postal Code
28239
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralf U. Trappe, Prof.
First Name & Middle Initial & Last Name & Degree
Christoph Diekmann, Dr.
Facility Name
Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin II
City
Chemnitz
ZIP/Postal Code
09113
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mathias Hänel, PD Dr.
First Name & Middle Initial & Last Name & Degree
Andreas Thiel
Facility Name
DONAUISAR Klinikum Deggendorf, Innere Medizin II
City
Deggendorf
ZIP/Postal Code
94469
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Graf, PD Dr.
First Name & Middle Initial & Last Name & Degree
Regine Maier
Facility Name
St.-Johannes-Hospital
City
Dortmund
ZIP/Postal Code
44137
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralf G. Meyer, PD Dr.
First Name & Middle Initial & Last Name & Degree
Heidrun Hindahl, Dr.
First Name & Middle Initial & Last Name & Degree
Darina Kodzhabasheva, Dr.
First Name & Middle Initial & Last Name & Degree
Volker Hagen, Dr.
Facility Name
Gemeinschaftspraxis Dr. Mohm und Prange-Krex - Fachärzte für Innere Medizin und Hämatologie und Onkologie
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gabriele Prange-Krex, Dr.
First Name & Middle Initial & Last Name & Degree
Johannes Mohm, Dr.
Facility Name
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank Kroschinsky, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Rainer Ordemann, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Nael Alakel, Dr.
Facility Name
Universitätsklinikum Düsseldorf, Klinik f. Hämatologie, Onkologie und klinische Immunologie
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guido Kobbe, Prof.
First Name & Middle Initial & Last Name & Degree
Mustafa Kondakci, Dr.
First Name & Middle Initial & Last Name & Degree
Thomas Schröder, Dr.
Facility Name
Marien Hospital Düsseldorf
City
Düsseldorf
ZIP/Postal Code
40479
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aristoteles Giagounidis, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Maika Klaiber-Hakimi, Dr.
First Name & Middle Initial & Last Name & Degree
Stefanie Gröpper, Dr.
First Name & Middle Initial & Last Name & Degree
Daniela Fachin, Dr.
Facility Name
Helios Klinikum Erfurt GmbH, Zentrum f. Innere Medizin u. internistische Onkologie, Hämostaseologie
City
Erfurt
ZIP/Postal Code
99089
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Herbert G. Sayer, PD Dr.
First Name & Middle Initial & Last Name & Degree
Volker Schmidt, Dr.
First Name & Middle Initial & Last Name & Degree
Elke Richter, Dr.
Facility Name
Universitätsklinikum Erlangen, Med. Klinik 5, Hämatologie und internistische Onkologie
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernd Spriewald, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Stefan Krause, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Norbert Meidenbauer, Dr.
First Name & Middle Initial & Last Name & Degree
Katja San Nicoló, Dr.
Facility Name
St.-Antonius-Hospital Eschweiler, Klinik für Hämatologie und Onkologie
City
Eschweiler
ZIP/Postal Code
52249
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Staib, PD Dr.
First Name & Middle Initial & Last Name & Degree
Frank Schlegel, Dr.
First Name & Middle Initial & Last Name & Degree
Susan Wehle-Ilka, Dr.
Facility Name
Universitätsklinikum Essen, Klinik f. Hämatologie
City
Essen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Dürig, Prof.
First Name & Middle Initial & Last Name & Degree
Alexander Carpinteiro, Dr.
First Name & Middle Initial & Last Name & Degree
Andreas Hüttmann, PD. Dr.
First Name & Middle Initial & Last Name & Degree
Alexander Röth, Dr.
First Name & Middle Initial & Last Name & Degree
Joachim R. Göthert, Dr.
First Name & Middle Initial & Last Name & Degree
Julia Baum, Dr.
Facility Name
Universitätsklinikum Freiburg, Klinik f. Innere Medizin, Hämatologie, Onkologie u. Stammzelltransplantation
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Reinhard Marks, PD Dr.
First Name & Middle Initial & Last Name & Degree
Anna-Lena Illert, Dr.
First Name & Middle Initial & Last Name & Degree
Cornelius Miething, Dr.
First Name & Middle Initial & Last Name & Degree
Stefanie Kreutmair, Dr.
First Name & Middle Initial & Last Name & Degree
Rainer Claus, PD Dr.
Facility Name
Universitätsmedizin Greifswald, Klinik u. Poliklinik f. Innere Medizin C, Hämatologie u. Onkologie-, Transplantationszentrum
City
Greifswald
ZIP/Postal Code
17475
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Schmidt, Prof.
First Name & Middle Initial & Last Name & Degree
William Krüger, Prof.
First Name & Middle Initial & Last Name & Degree
Christian Späth, Dr.
First Name & Middle Initial & Last Name & Degree
Carsten Hirt, Dr.
Facility Name
Universitätsmedizin Göttingen, Zentrum f. Innere Medizin, Klinik f. Hämatologie und Medizinische Onkologie
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wolfram Jung, Dr.
First Name & Middle Initial & Last Name & Degree
Justin Hasenkamp, Dr.
First Name & Middle Initial & Last Name & Degree
Gerald G. Wulf, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Friederike Braulke, Dr.
Facility Name
Katholisches Krankenhaus Hagen gGmbH, St.-Marien-Hospital, Klinik f. Hämatologie und Onkologie
City
Hagen
ZIP/Postal Code
58095
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans-Walter Lindemann, Dr.
First Name & Middle Initial & Last Name & Degree
Cordula Maciejewski
Facility Name
Universitätsklinikum Hamburg-Eppendorf (UKE), II. Med. Klinik u. Poliklinik, Onkologie, Hämatologie, KMT
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judith Dierlamm, Prof.
First Name & Middle Initial & Last Name & Degree
Lars Arne Berger, Dr.
First Name & Middle Initial & Last Name & Degree
Carola Reimer, Dr.
First Name & Middle Initial & Last Name & Degree
Anja Coym, Dr.
Facility Name
Asklepios Klinik Altona, II. Med.Abt. f. Hämatologie und internistische Onkologie, Stammzelltransplantation
City
Hamburg
ZIP/Postal Code
22763
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans-Jürgen Salwender, Dr.
First Name & Middle Initial & Last Name & Degree
Murwan Ayoub, Dr.
Facility Name
Universitätsklinikum Heidelberg, Med. Klinik - Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mathias Witzens-Harig, Prof.
First Name & Middle Initial & Last Name & Degree
Patrick Wuchter, Dr.
First Name & Middle Initial & Last Name & Degree
Iris Breitkreutz, Dr.
First Name & Middle Initial & Last Name & Degree
Könül Pashayeva, Dr.
First Name & Middle Initial & Last Name & Degree
Katharina Lisenko, Dr.
First Name & Middle Initial & Last Name & Degree
Johann W. Schmier, Dr.
Facility Name
Universitätsklinikum des Saarlandes, Klinik f. Innere Medizin I Hämatologie & Onkologie
City
Homburg
ZIP/Postal Code
66421
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Pfreundschuh, Prof.
First Name & Middle Initial & Last Name & Degree
Jörg Bittenbring, Dr.
Facility Name
Klinikum Idar-Oberstein GmbH, Medizinische Klinik I
City
Idar-Oberstein
ZIP/Postal Code
55743
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Roemer, Dr.
First Name & Middle Initial & Last Name & Degree
Marina Bischoff, Dr.
First Name & Middle Initial & Last Name & Degree
Maritza Lar-Valverde, Dr.
First Name & Middle Initial & Last Name & Degree
Johannes Schneider, Dr.
Facility Name
Universitätsmedizin Jena, Klinik f. Innere Medizin II, Abteilung Hämatologie u. Internistische Onkologie
City
Jena
ZIP/Postal Code
07747
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sebastian Scholl, PD Dr.
First Name & Middle Initial & Last Name & Degree
Thomas Ernst, PD Dr.
Facility Name
Städtisches Klinikum Karlsruhe, Med. Klinik III, Hämatologie und Onkologie
City
Karlsruhe
ZIP/Postal Code
76133
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Bentz, Prof.
First Name & Middle Initial & Last Name & Degree
Joy Dickinson, Dr.
Facility Name
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik f. Innere Medizin II - Hämatologie und Onkologie
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christiane Pott, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Michael Kneba, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Sebastian Böttcher, PD Dr.
First Name & Middle Initial & Last Name & Degree
Matthias Ritgen, Dr.
Facility Name
Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin, Klinik f. Innere Medizin
City
Koblenz
ZIP/Postal Code
56068
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dirk Niemann, Dr.
First Name & Middle Initial & Last Name & Degree
Ralph Naumann, Prof.
First Name & Middle Initial & Last Name & Degree
Christian Breitbarth-Girmscheid, Dr.
First Name & Middle Initial & Last Name & Degree
Elisabeth Fritz, Dr.
Facility Name
Praxisklinik f. Hämatologie und Onkologie Koblenz
City
Koblenz
ZIP/Postal Code
56068
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jörg Thomalla, Dr.
First Name & Middle Initial & Last Name & Degree
Christoph von Roye, Dr.
First Name & Middle Initial & Last Name & Degree
Rudolf Weide, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Geothy Chakupurakal, Dr.
First Name & Middle Initial & Last Name & Degree
Jochen Heymanns, Dr.
First Name & Middle Initial & Last Name & Degree
Florence Klose, Dr.
Facility Name
Uniklinik Köln, Klinik I für Innere Medizin
City
Köln
ZIP/Postal Code
50937
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kai Hübel, Prof.
First Name & Middle Initial & Last Name & Degree
Peter Borchmann, Prof.
First Name & Middle Initial & Last Name & Degree
Bastian von Tresckow, Dr.
First Name & Middle Initial & Last Name & Degree
Christian Pallasch, Dr.
First Name & Middle Initial & Last Name & Degree
Armin Tuchscherer, Dr.
First Name & Middle Initial & Last Name & Degree
Thomas Zander, PD Dr.
First Name & Middle Initial & Last Name & Degree
Stephanie Sasse, Dr.
Facility Name
Onkologisch-Hämatologische Praxis Dr. Vehling-Kaiser
City
Landshut
ZIP/Postal Code
84028
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ursula Vehling-Kaiser, Dr.
First Name & Middle Initial & Last Name & Degree
Mike Haberkorn
First Name & Middle Initial & Last Name & Degree
Chrysantha Langer, Dr.
First Name & Middle Initial & Last Name & Degree
Franziskus Finsterwalder, Dr.
First Name & Middle Initial & Last Name & Degree
Michael Sohm, Dr.
Facility Name
Klinikum Landshut gGmbH, Med. Klinik III, Hämatologie/Internistische Onkologie
City
Landshut
ZIP/Postal Code
84034
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Kempf
First Name & Middle Initial & Last Name & Degree
Heiko Merkle, Dr.
First Name & Middle Initial & Last Name & Degree
Gabriela Totok, Dr.
First Name & Middle Initial & Last Name & Degree
Adrian Schembor
Facility Name
Caritas-KHLebach, Gemeinschaftspraxis f. Hämatologie und Onkologie, Onkologisches Zentrum Lebach
City
Lebach
ZIP/Postal Code
66822
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephan Kremers, Dr.
First Name & Middle Initial & Last Name & Degree
Stefan Bauer, PD Dr.
First Name & Middle Initial & Last Name & Degree
Alessandro Falgiatore, Dr.
First Name & Middle Initial & Last Name & Degree
Celine Szysnik, Dr.
First Name & Middle Initial & Last Name & Degree
Hauke Täger, Dr.
Facility Name
Universitätsklinikum Leipzig AöR, selbständige Abteilung f. Hämatologie und Internistische Onkologie, Hämostaseologische Ambulanz
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dietger Niederwieser, Prof.
First Name & Middle Initial & Last Name & Degree
Gerhard Behre, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Vladan Vucinic, Dr.
First Name & Middle Initial & Last Name & Degree
Song-Yau Wang, Dr.
First Name & Middle Initial & Last Name & Degree
Sebastian Schwind
First Name & Middle Initial & Last Name & Degree
Christine Döhring
Facility Name
Klinikum Lippe GmbH, Onkologie und Hämatologie
City
Lemgo
ZIP/Postal Code
32657
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank Hartmann, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Tanja Hesse, Dr.
First Name & Middle Initial & Last Name & Degree
Susanne Horstmeyer, Dr.
Facility Name
Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Med. Klinik A
City
Ludwigshafen
ZIP/Postal Code
67063
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Hoffmann, Dr.
First Name & Middle Initial & Last Name & Degree
Michael Uppenkamp, Prof.
Facility Name
Universitätsklinikum Magdeburg AöR, Klinik f. Hämatologie und Onkologie
City
Magdeburg
ZIP/Postal Code
39120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Enrico Schalk, Dr.
First Name & Middle Initial & Last Name & Degree
Christian Krogel, Dr.
First Name & Middle Initial & Last Name & Degree
Denise Wolleschak, Dr.
Facility Name
Universitätsmedizin der Univ. Mainz, III. Med. Klinik u. Poliklinik
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georg Heß, PD Dr.
First Name & Middle Initial & Last Name & Degree
Hans-Joachim Beck, Dr.
First Name & Middle Initial & Last Name & Degree
Eva-Maria Wagner, Dr.
First Name & Middle Initial & Last Name & Degree
Oliver Kriege
Facility Name
Johannes Wiesling Klinikum Minden, Klinik f. Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin
City
Minden
ZIP/Postal Code
32429
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hans-Heinrich Wöltjen, Dr.
First Name & Middle Initial & Last Name & Degree
Kai Wille, Dr.
First Name & Middle Initial & Last Name & Degree
Philip Dargatz, Dr.
Facility Name
Klinikum der Universität München, Med. Klinik und Poliklinik III
City
München
ZIP/Postal Code
81377
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Schmidt, Dr.
Email
Christian_Schmidt@med.uni-muenchen.de
First Name & Middle Initial & Last Name & Degree
Martin Dreyling, Prof.
First Name & Middle Initial & Last Name & Degree
Christian Schmidt, Dr.
Facility Name
Klinikum Rechts der Isar, III. Med. Klinik - Hämatologie und Onkologie
City
München
ZIP/Postal Code
81675
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulrich Keller, Prof.
First Name & Middle Initial & Last Name & Degree
Christian Bogner, Dr.
First Name & Middle Initial & Last Name & Degree
Irina Kerle, Dr.
Facility Name
Universitätsklinikum Münster, Med. Klinik A, Translationale Onkologie / Lymphome
City
Münster
ZIP/Postal Code
48149
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georg Lenz, Prof.
First Name & Middle Initial & Last Name & Degree
Christoph Schliemann, PD Dr.
First Name & Middle Initial & Last Name & Degree
Andrea Kerkhoff, Dr.
First Name & Middle Initial & Last Name & Degree
Arik Schulze, Dr.
First Name & Middle Initial & Last Name & Degree
Julia Reusch, Dr.
First Name & Middle Initial & Last Name & Degree
Ursula Stalmann
Facility Name
Klinikum Nürnberg,5. Medizinische Klinik, Onkologie / Hämatologie
City
Nürnberg
ZIP/Postal Code
90419
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kerstin Schäfer-Eckart, Dr.
First Name & Middle Initial & Last Name & Degree
Knut Wendelin, Dr.
First Name & Middle Initial & Last Name & Degree
Josef Birkmann, PD Dr.
Facility Name
Klinikum Oldenburg gGmbH, Med. Klinik II
City
Oldenburg
ZIP/Postal Code
26133
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernd Metzner, PD Dr.
First Name & Middle Initial & Last Name & Degree
Ruth Thole, Dr.
First Name & Middle Initial & Last Name & Degree
Andreas Voß, Dr.
Facility Name
Klinikum Ernst von Bergmann Potsdam gGmbH, Zentrum f. Innere Medizin, Klinik f. Hämatologie und Onkologie
City
Potsdam
ZIP/Postal Code
14467
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georg Maschmeyer-Krull, Prof.
First Name & Middle Initial & Last Name & Degree
Frank Breywisch, Dr,
Facility Name
KH Barmherzige Brüder, Klinik f. Onkologie und Hämatologie
City
Regensburg
ZIP/Postal Code
93049
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernhard Heilmeier, Dr.
First Name & Middle Initial & Last Name & Degree
Anke Schlenska-Lange, Dr.
First Name & Middle Initial & Last Name & Degree
Veronika Berberich, Dr.
First Name & Middle Initial & Last Name & Degree
Jan Braess, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Nicolas Moosmann, Dr.
Facility Name
Universitätsmedizin Rostock, Abt. f. Hämatologie und Onkologie, Klinik und Poliklinik für Innere Medizin
City
Rostock
ZIP/Postal Code
18057
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Junghanß, Prof.
First Name & Middle Initial & Last Name & Degree
Christina Große-Thie, Dr.
First Name & Middle Initial & Last Name & Degree
Larissa Henze, Dr.
First Name & Middle Initial & Last Name & Degree
Brigitte Kragl, Dr.
Facility Name
Klinikum Stuttgart - Katharinenhospital, Klinik f. Hämatologie und Onkologie
City
Stuttgart
ZIP/Postal Code
70174
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerald Illerhaus, Prof.
First Name & Middle Initial & Last Name & Degree
Dennis Hahn, Dr.
First Name & Middle Initial & Last Name & Degree
Philippe Nono, Dr.
First Name & Middle Initial & Last Name & Degree
Kristina Hadler-Mikesch, Dr.
Facility Name
Robert-Bosch-Krankenhaus, Abt.f. Hämatologie und Onkologie
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Vöhringer, Dr.
First Name & Middle Initial & Last Name & Degree
Sonja Martin, Dr.
First Name & Middle Initial & Last Name & Degree
Liza Bacchus, Dr.
Facility Name
Klinikum Traunstein, Hämatologie - Onkologie- Palliativmedizin
City
Traunstein
ZIP/Postal Code
83278
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas W. Kubin, Dr.
First Name & Middle Initial & Last Name & Degree
Florian Zettl, Dr.
First Name & Middle Initial & Last Name & Degree
Elke Hagenreiner, Dr.
First Name & Middle Initial & Last Name & Degree
Elisabeth Dietl, Dr.
First Name & Middle Initial & Last Name & Degree
Klaus Eberl, Dr.
Facility Name
Klinikum Mutterhaus der Borromäerinnen gGmbH, Okologisches Zentrum
City
Trier
ZIP/Postal Code
54290
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rolf Mahlberg, Dr.
First Name & Middle Initial & Last Name & Degree
Stefan Heidel, Dr.
Facility Name
Universitätsklinikum Tübingen, Med Klinik I, Innere Medizin II
City
Tübingen
ZIP/Postal Code
72026
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Sökler, Dr.
First Name & Middle Initial & Last Name & Degree
Martin Müller, PD Dr.
Facility Name
Universitätsklinikum Ulm, Klinik für Innere Medizin III
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephan Stilgenbauer, Prof.
First Name & Middle Initial & Last Name & Degree
Johannes Bloehdorn, Dr.
Facility Name
Klinikum Wolfsburg, Med. Klinik II
City
Wolfsburg
ZIP/Postal Code
38440
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steffen Neumann, Dr.
First Name & Middle Initial & Last Name & Degree
Nils Homann, Prof.
Facility Name
Universitätsklinikum Würzburg, Med. Klinik u. Poliklinik II /ZIM
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Max S. Topp, Prof.
First Name & Middle Initial & Last Name & Degree
Johannes Düll, Dr.
Facility Name
Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, SC Ematologia
City
Alessandria
ZIP/Postal Code
15121
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marco Ladetto, Dr.
First Name & Middle Initial & Last Name & Degree
Manuela Zanni, Dr.
First Name & Middle Initial & Last Name & Degree
Anna Baraldi, Dr.
First Name & Middle Initial & Last Name & Degree
Federico Monaco, Dr.
Facility Name
Policlinico S. Orsola Malpighi, Istituto di Ematologia e Oncologia Medica Seragnoli
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vittorio Stefoni, Dr.
Facility Name
Comprensorio Sanitario di Bolzano, Ematologia e trapianto di midollo osseo
City
Bolzano
ZIP/Postal Code
39100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Mian, Dr.
Facility Name
Spedali Civili, Struttura Complessa di Ematologia
City
Brescia
ZIP/Postal Code
25123
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Re, Dr.
Facility Name
Ospedale Businco, UO Ematologia - CTMO
City
Cagliari
ZIP/Postal Code
09121
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Giuseppina Cabras, Dr.
Facility Name
ASO S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
City
Cuneo
ZIP/Postal Code
12100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudia Castellino, Dr.
Facility Name
AOU Policlinico Careggi, Unità Funzionale di Ematologia
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luigi Rigacci, Dr.
Facility Name
IRCCS AOU S. Martino - IST, Clinica Ematologia
City
Genova
ZIP/Postal Code
16132
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marco Gobbi, Prof.
Facility Name
IRCCS AOU S. Martino - IST, Ematologia
City
Genova
ZIP/Postal Code
16132
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angela Congiu, Dr.
Facility Name
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Ematologia
City
Meldola (FC)
ZIP/Postal Code
47014
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerardo Musuraca, Dr.
Facility Name
Istituto Scientifico San Raffaele, Unità Ricerca Clinica Linfomi
City
Milano
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andres Ferreri, Dr.
Facility Name
Ospedale Niguarda, Struttura Complessa di Ematologia
City
Milano
ZIP/Postal Code
20162
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiara Rusconi, Dr.
Facility Name
Università di Modena e Reggio Emilia Policlinico - COM Centro Oncologico Modenese, Dipartimento di Oncologia ed Ematologia
City
Modena
ZIP/Postal Code
41124
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Franco Narni, Prof.
Facility Name
Ospedale S. Gerardo, Divisione di Ematologia
City
Monza
ZIP/Postal Code
20052
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Bolis, Dr.
Facility Name
"IRCCS Istituto Nazionale dei Tumori di Napoli - Pascale", Ematologia Oncologica
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonello Pinto, Dr.
Facility Name
AOU Maggiore della Carità - Università del Piemonte Orientale, S.C.D.U Ematologia
City
Novara
ZIP/Postal Code
28100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gianluca Gaidano, Prof.
Facility Name
AO Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia
City
Palermo
ZIP/Postal Code
90146
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caterina Patti, Dr.
Facility Name
IRCCS Fondazione Policlinico San Matteo, Clinica Ematologia
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luca Arcaini, Prof.
Facility Name
Azienda Ospedaliera Pisana Ospedale "S.Chiara", Dipartimento di Oncologia Divisione di Ematologia
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Petrini, Prof.
Facility Name
Ospedale S. Maria delle Croci, U.O di Ematologia
City
Ravenna
ZIP/Postal Code
48121
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monica Tani, Dr.
Facility Name
Azienda Ospedaliera Bianchi, Melacrino, Morelli, Divisione di Ematologia
City
Reggio Calabria
ZIP/Postal Code
89125
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caterina Stelitano, Dr.
Facility Name
Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Ematologia
City
Reggio Emilia
ZIP/Postal Code
42123
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Merli, Dr.
Facility Name
Ospedale degli Infermi, U.O. Ematologia
City
Rimini
ZIP/Postal Code
47923
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annalia Molinari, Dr.
Facility Name
Policlinico Tor Vergata, UOC Oncoematologia
City
Roma
ZIP/Postal Code
00133
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Cantonetti, Prof
Facility Name
Università La Sapienza, Ematologia
City
Roma
ZIP/Postal Code
00161
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maurizio Martelli, Prof.
Facility Name
Casa Sollievo della Sofferenza, U.O. Ematologia
City
San Giovanni Rotondo
ZIP/Postal Code
71013
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Cascavilla, Dr.
Facility Name
A.O. Città della Salute e della Scienza, SC Ematologia
City
Torino
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Umberto Vitolo, Dr.
Facility Name
A.O. U. Città della Salute e della Scienza, S C Ematologia U
City
Torino
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Federica Cavallo, Dr.
Facility Name
Ospedale Cà Foncello, U.O.C. Ematologia
City
Treviso
ZIP/Postal Code
31100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Piero Maria Stefani, Dr.
Facility Name
Ospedale Cardinale Panico, Divisione di Ematologia
City
Tricase
ZIP/Postal Code
73054
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincenzo Pavone, Dr.
Facility Name
ASUI Integrata di Udine, Clinica Ematologia
City
Udine
ZIP/Postal Code
33100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francesco Zaja, Prof.
Facility Name
Ospedale Policlinico G.B. Rossi, "Centro trapianto midollo osseo Ematologia"
City
Verona
ZIP/Postal Code
37134
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabio Benedetti, Dr.
Facility Name
Ospedale S. Bortolo, Ematologia
City
Vicenza
ZIP/Postal Code
36100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlo Visco, Dr.
First Name & Middle Initial & Last Name & Degree
Maria Chiara Tisi, Dr.
First Name & Middle Initial & Last Name & Degree
Omar Perbellini, Dr.
Facility Name
Haukeland University Hospital , Dept. of Oncology and Medical Physics
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Turid Bjørnevik, Dr.
Facility Name
Oslo University Hospital, Dept of Oncology
City
Oslo
ZIP/Postal Code
0310
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arne Kolstad, Dr.
Facility Name
Stavanger University Hospital, Division for Hematology&Oncology
City
Stavanger
ZIP/Postal Code
4011
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Meyer, Dr.
Facility Name
UNN Tromsø, Oncology Dep
City
Tromsø
ZIP/Postal Code
9038
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fredrik Sund
Facility Name
St. Olavs Hospital, Department of Oncology
City
Trondheim
ZIP/Postal Code
7006
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karin Inger Martina Fahl Wader, MD Phd.
Facility Name
Sahlgrenska University Hospital, Section of Hematology and Coagulation, Dept of internal medicine
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catharina Lewerin
Facility Name
University Hospital, Dept of Hematolgy
City
Linköping
ZIP/Postal Code
581 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ingemar Lagerlöf, Dr.
First Name & Middle Initial & Last Name & Degree
Ronald Svensson, Dr.
Facility Name
Sunderbyn Hospital, Dept of Medicine
City
Lulea
ZIP/Postal Code
971 80
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lena Brandefors, Dr.
Facility Name
Skane University Hospital
City
Lund
ZIP/Postal Code
221 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman, MD
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman, MD
Facility Name
Karolinska University Hospital, Center of Hematology
City
Stockholm
ZIP/Postal Code
141 86
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristina Sonnevi, Dr.
First Name & Middle Initial & Last Name & Degree
Torsten Dahlen, Dr.
First Name & Middle Initial & Last Name & Degree
Fredrik Celsing, Dr.
First Name & Middle Initial & Last Name & Degree
Maria Ljungqvist, Dr.
Facility Name
Norrland University Hospital, Dept of Oncology
City
Umea
ZIP/Postal Code
901 85
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karin Papworth
First Name & Middle Initial & Last Name & Degree
Sara Sjöström, Dr.
Facility Name
Academic Hospital, Dept of Oncology
City
Uppsala
ZIP/Postal Code
751 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Laurell, Dr.
First Name & Middle Initial & Last Name & Degree
Ingrid Glimelius, Dr.
Facility Name
Örebro University Hospital, Dept of Oncology
City
Örebro
ZIP/Postal Code
701 85
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karin Nyström, Dr.
First Name & Middle Initial & Last Name & Degree
David Löfgren
First Name & Middle Initial & Last Name & Degree
Urban Jerlström

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

We'll reach out to this number within 24 hrs